EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans

Annelies Van Hoecke,Lies Schoonaert,Robin Lemmens,Mieke Timmers,Kim A Staats,Angela S Laird,Elke Peeters,Thomas Philips,An Goris,Bénédicte Dubois,Peter M Andersen,Ammar Al-Chalabi,Vincent Thijs,Ann M Turnley,Paul W van Vught,Jan H Veldink,Orla Hardiman,Ludo Van Den Bosch,Paloma Gonzalez-Perez,Philip Van Damme,Robert H Brown,Leonard H van den Berg,Wim Robberecht
DOI: https://doi.org/10.1038/nm.2901
IF: 82.9
2012-08-26
Nature Medicine
Abstract:Epha4 is a receptor involved in axonal repulsion. Wim Robberecht and his colleagues report that genetic or pharmacological inhibition of Epha4 is protective in rodent and zebrafish models of amyotrophic lateral sclerosis. In humans, expression of Epha4 inversely correlates with disease onset and survival, and in two patients, mutations in Epha4 are associated with longer survival, suggesting Epha4 may be targeted therapeutically to prevent axonal degeneration.
biochemistry & molecular biology,cell biology,medicine, research & experimental
What problem does this paper attempt to address?